Exact Sciences Corporation $EXAS Shares Acquired by ASR Vermogensbeheer N.V.

ASR Vermogensbeheer N.V. lifted its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 13.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,143 shares of the medical research company’s stock after acquiring an additional 2,023 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Exact Sciences were worth $911,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in EXAS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Exact Sciences by 120.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock worth $135,453,000 after buying an additional 1,707,287 shares during the period. Nuveen LLC acquired a new stake in Exact Sciences in the first quarter worth $45,334,000. Price T Rowe Associates Inc. MD increased its position in Exact Sciences by 11.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company’s stock worth $277,225,000 after buying an additional 643,631 shares during the period. Vanguard Group Inc. increased its position in Exact Sciences by 3.6% in the first quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company’s stock worth $763,535,000 after buying an additional 617,384 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new stake in Exact Sciences in the first quarter worth $20,803,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Exact Sciences news, Director James Edward Doyle sold 1,485 shares of the firm’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $42.02, for a total transaction of $62,399.70. Following the completion of the sale, the director directly owned 59,962 shares in the company, valued at approximately $2,519,603.24. This trade represents a 2.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company’s stock.

Exact Sciences Trading Up 0.9%

Shares of NASDAQ EXAS opened at $56.72 on Friday. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $72.83. The firm has a market capitalization of $10.74 billion, a PE ratio of -10.45, a PEG ratio of 5.24 and a beta of 1.24. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. The business has a 50-day moving average price of $49.57 and a two-hundred day moving average price of $50.09.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.24. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The firm had revenue of $811.09 million during the quarter, compared to analyst estimates of $774.43 million. During the same period last year, the company posted ($0.09) EPS. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. As a group, analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EXAS. Piper Sandler dropped their target price on Exact Sciences from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Zacks Research lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 4th. Evercore ISI dropped their target price on Exact Sciences from $68.00 to $64.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Royal Bank Of Canada dropped their target price on Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 7th. Finally, Barclays increased their target price on Exact Sciences from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $68.52.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.